Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,064 recruiting studies in this area right now.
By phase
- Not applicable3,004
- Phase 21,060
- Phase 1794
- Phase 1/Phase 2439
- Phase 3436
- Phase 4233
- Phase 2/Phase 398
Top conditions
- Multiple Myeloma328
- Multiple Sclerosis328
- Asthma194
- Lymphoma178
- Rheumatoid Arthritis131
- Type 1 Diabetes131
- Atopic Dermatitis124
- Systemic Lupus Erythematosus119
- Acute Lymphoblastic Leukemia118
- HIV Infections106
- Chronic Lymphocytic Leukemia96
- Autoimmune Diseases78
- Follicular Lymphoma70
- Rheumatoid Arthritis (RA)68
- Hodgkin Lymphoma64
- Diabetes Mellitus, Type 163
- Leukemia63
- Type 1 Diabetes Mellitus63
Leading sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)97
- Institute of Hematology & Blood Diseases Hospital, China85
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris65
- AstraZeneca64
- M.D. Anderson Cancer Center58
- Novartis Pharmaceuticals58
- Mayo Clinic50
- City of Hope Medical Center48
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California498
- Maryland199
- Alabama178
- Florida152
- Arizona149
- Massachusetts117
- New York116
- Texas112
- Illinois82
- Colorado81
Recruiting studies6,064 total
- NCT07011810RecruitingPhase 2
Axatilimab for sclerotic chronic graft-versus-host disease
This study tests a new drug called axatilimab for people with a specific type of chronic graft-versus-host disease (cGVHD) that causes hardening or thickening of the skin or joints. cGVHD is a complication after a stem cell transplant where the donor's immune cells attack your body. The study aims to see if axatilimab can improve these sclerotic symptoms. If you have this condition and it was recently diagnosed (within the last year), you might qualify to participate.
Tampa, FloridaAges 18 years+ - NCT07006012Recruiting
Study of RGL-305 for lymphoma with minimal residual disease
This trial tests if a new treatment called RGL-305 can help people with lymphoma who still have tiny amounts of cancer cells left after previous treatment. It is for those whose disease has responded to prior therapy but is not completely gone at the genetic level.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07008170Recruiting
Combined gallbladder and bile duct stone removal
This trial tests a one-time procedure that removes stones from both the gallbladder and the bile duct. It may help people who need both surgeries or who couldn't be treated with endoscopy alone.
MinyaAges 18–75 - NCT07012447RecruitingPhase 2
Venetoclax with azacytidine for newly diagnosed T-cell leukemia
This trial tests a combination of venetoclax and azacytidine for people with certain types of T-cell acute lymphoblastic leukemia (T-ALL) that haven't been treated yet. It focuses on cases with specific genetic changes and aims to see if this drug pair can help control the disease.
Suzhou, JiangsuAges 14 years+ - NCT07006506RecruitingPhase 2
Belumosudil to prevent graft-versus-host disease after transplant
This study tests whether a drug called belumosudil can help prevent graft-versus-host disease (GVHD) after a stem cell transplant. It is for people who have had a recent transplant and are at risk for GVHD.
Basking Ridge, New JerseyAges 18 years+ - NCT07005479Recruiting
Long-term lupus study at Peking University Hospital
This study looks at the long-term health of people with lupus. It aims to understand how the disease progresses over time.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07013110RecruitingPhase 2
AI-guided precision therapy for active rheumatoid arthritis
This study tests a new, AI-powered treatment approach for rheumatoid arthritis. It's for people with active disease who haven't used certain biologic or targeted therapies in the last 6 months.
SingaporeAges 21 years+ - NCT07013435Recruiting
Resilience training for lymphoma survivors
This study tests a program to help lymphoma survivors build resilience and improve long-term quality of life after treatment. It's a behavioral intervention, not a drug trial, that focuses on coping and well-being.
Boston, MassachusettsAges 18 years+ - NCT07005726Enrolling by invitationPhase 4
BCG revaccination with DTP3 to reduce infant deaths in Africa
This study tests whether giving another BCG vaccine (the one for tuberculosis) at the same time as the third DTP shot can help reduce serious infections and deaths in babies in Africa. If your baby is healthy and getting their routine DTP3, this could be an option to possibly boost their overall protection.
BissauAges 3 months–6 months - NCT07012304RecruitingPhase 1/Phase 2
Testing gecacitinib for chronic graft-versus-host disease after 2 or more treatments
This trial tests a new drug, gecacitinib, for patients with moderate to severe chronic graft-versus-host disease (cGVHD) that has not improved after 2 to 5 prior treatments. It aims to see if the drug is safe and effective.
BeijingAges 18 years+ - NCT07011147Recruiting
Real-world test of automated insulin delivery in primary care
This study tests if an automated insulin delivery system (the iLet bionic pancreas) works well in real-world primary care settings for people with type 1 or type 2 diabetes. It aims to see if this technology can help manage blood sugar more easily.
Aurora, ColoradoAges 18–89 - NCT07010380Recruiting
Finding parathyroid glands with AI imaging during thyroid surgery
This trial uses a special camera and AI software during thyroid or parathyroid surgery to help surgeons identify and protect the parathyroid glands. The goal is to reduce complications like low calcium levels after surgery.
Fuzhou, FJAges 18 years+ - NCT07003555RecruitingPhase 1
Dual-target CAR-T therapy for multiple myeloma with extramedullary disease
This trial tests a new CAR-T cell treatment that targets two proteins (BCMA and CD19) on myeloma cells. It is for patients whose multiple myeloma has come back or stopped responding to other treatments and has spread to tissues outside the bone marrow.
ShanghaiAges 18–75 - NCT06999954Recruiting
Global survey for Shwachman-Diamond syndrome and related conditions
This trial is a global survey and registry for people with Shwachman-Diamond Syndrome and related inherited blood disorders. It aims to connect patients, families, and researchers to better understand these conditions and improve care.
Woburn, MassachusettsAges Any age - NCT06999031RecruitingEarly Phase 1
CG-105-12 for relapsed/refractory multiple myeloma
This trial tests a new CAR-T cell therapy called CG-105-12 for people with multiple myeloma that has come back or stopped responding to other treatments. It aims to see if this therapy can help when at least 3 prior treatments have failed.
Nanchang, JiangxiAges 18–75 - NCT05159856Recruiting
Early checks for long-term complications in young type 1 diabetes
This study looks for early signs of long-term complications in children and teens who have type 1 diabetes for more than a year. It may help your clinic spot problems sooner, when treatment could be easier.
Herlev, HerlevAges 6–18 - NCT06119685RecruitingPhase 1/Phase 2
IDP-023 alone or with other antibodies for blood cancers
This trial tests an experimental drug, IDP-023, given alone or with antibody therapies for people with advanced blood cancers like multiple myeloma or non-Hodgkin lymphoma that have not responded to previous treatments. The goal is to see if it can shrink tumors or slow the disease.
Los Angeles, CaliforniaAges 18 years+ - NCT05921305RecruitingPhase 3
Low-dose methotrexate plus steroid for early acute GVHD
This Phase 3 trial tests whether a specific low-dose medication (methotrexate) together with standard steroid treatment can improve early outcomes in patients with acute graft-versus-host disease after a stem cell transplant. It may help control the immune reaction that attacks the body after transplant.
Beijing, Beijing MunicipalityAges 15–65 - NCT06340750RecruitingPhase 1
BAFF CAR-T cells for lupus that hasn't improved with standard treatments
This trial tests a new type of cell therapy called BAFF CAR-T cells (LMY-920) for lupus that hasn't gotten better with standard treatments. It aims to see if these special immune cells can help calm the overactive immune system in lupus.
Columbus, OhioAges 18–65 - NCT07000110Recruiting
Anifrolumab and risk study for lupus patients
This study looks at potential risks of the lupus medication anifrolumab in people with moderate to severe SLE. It focuses on serious infections and malignancies to see how safe the treatment is.
CopenhagenAges 18–130 - NCT07001280Recruiting
Garadacimab for hereditary angioedema (HAE)
This study looks at how well a drug called garadacimab works and how safe it is for people with hereditary angioedema (HAE), a condition that causes sudden swelling. It tests the drug in people who are starting it for the first time as part of their regular care.
Phoenix, ArizonaAges 12 years+ - NCT07002034RecruitingPhase 2
RE104 for adjustment disorder related to cancer or other serious illnesses
This trial is testing a new medication (RE104) for people who have adjustment disorder with depressed mood or anxiety because of a serious medical condition like cancer, ALS, MS, Parkinson's, or lung fibrosis. It's a study to see if the drug is safe and reduces symptoms.
Birmingham, AlabamaAges 18–80 - NCT06997627RecruitingPhase 1/Phase 2
Safety and immune response study of GC3111B vaccine in healthy adults
This trial tests a new vaccine called GC3111B to see if it is safe and helps the body build protection against diphtheria, tetanus, and pertussis (whooping cough). It is for healthy adults who have not had a similar vaccine in the last 2 years.
SeoulAges 19–64 - NCT07002203RecruitingPhase 1/Phase 2
Personalized cancer vaccine trial for solid tumors
This trial tests a custom-made vaccine designed to train your immune system to fight your specific cancer. It may be an option if you have advanced cancer that stopped responding to treatment or early-stage cancer with a high risk of coming back.
BangkokAges 20 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,064 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,178 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.